ArticleMedicine2025
Exploration of upstream and downstream mechanisms of the TAGLN2 gene in pulmonary arterial hypertension.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study systematically explored the upstream and downstream mechanisms of the TAGLN2 gene regulated by DNA methylation and its succinylation modification in the pathogenesis of pulmonary arterial hypertension (PAH) by integrating Mendelian randomization and mediation analysis. The results showed that DNA methylation sites cg13892570 and cg16107628 significantly downregulated TAGLN2 expression (β = -0.53 and -0.61, P < .05), indirectly reducing the risk of PAH. The mediating effects of TAGLN2 accounted for 86.46% and 97.65% of the total effect, respectively. Further analysis indicated that TAGLN2 might promote PAH progression through immune and metabolic pathways: on the one hand, by activating HLA DR+ monocytes (mediation proportion 6.15%), it exacerbated pulmonary vascular inflammatory responses; on the other hand, by increasing the levels of eicosadienoic acid (mediation proportion 5.21%) and cysteinyl dipeptide (mediation proportion 3.15%), it induced oxidative stress and lipid metabolism disorders. Bioinformatics validation suggested that TAGLN2 was significantly overexpressed in the lung tissues of PAH patients (P < .05), and its succinylation modification might enhance the pro-PAH effect by altering protein stability and function. This study first proposed the "DNA methylation-TAGLN2 succinylation-immune/metabolic" regulatory axis, providing new ideas and potential targets for the epigenetic mechanism and precise treatment of PAH. However, the relevant conclusions still need to be further verified by subsequent experiments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.